- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT05269485
Hypofractie-radiotherapie voor lokaal gevorderde niet-kleincellige longkanker
Hypofraction Radiotherapy Followed by Immune Checkpoint Inhibitors for Locally Advanced Non-small Cell Lung Cancer: A Phase II Trial
Definitive concurrent chemoradiotherapy followed by durvalumab (Pacific protocol) has been the standard modality for stage III locally advanced non-small cell lung cancer. In spite of the median overall survival of 47.5 months, there still existed 38.5% and 6.9% patients who finally developed intra-thorax and extra-thorax recurrence respectively in long-term follow-up. The relatively low local control rate has been the bottleneck for further improvement of overall survival. Hypofraction radiotherapy has been validated to be able to increase the local control rate in two prospective trials. Therefore, this trial is designed to explore the safety and primary efficacy of hypofraction radiotherapy followed by immune checkpoint inhibitors for stage III locally advanced non-small cell lung cancer.
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
Trial title: Hypofraction radiotherapy followed by immune checkpoint inhibitors for locally advanced non-small cell lung cancer: A phase II clinical trial.
Trial objective: To explore the safety and primary efficacy of hypofraction radiotherapy followed by immune checkpoint inhibitors for stage III locally advanced non-small cell lung cancer.
Trial Design: To enroll 36 patients diagnosed with stage III locally advanced non-small cell lung cancer to receive hypofraction radiotherapy (18 patients receiving high dose of 60 (Gray, Gy) /15 (fraction, f) and 18 patients receiving low dose of 48Gy/12f) followed by 1-year maintenance of immune checkpoint inhibitors.
Inclusion Criteria: a. 18-70 years old; b. Eastern Cooperative Oncology Group (ECOG) 0-1; c. non-small cell lung cancer including squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma, large-cell carcinoma; d. wild-type of driven genes; e. stage II-III (AJCC 8th Edition) confirmed by cranial MRI, chest CT, abdominal ultrasonograph, bone scan or cranial MRI and Positron Emission Tomography (PET-CT); f. surgically unresectable or deny of surgery; g. signature of inform consent.
Exclusion Criteria: a. younger than 18 years old or older than 70 years old; b. ECOG>1; c. small-cell lung cancer and other neuroendocrine carcinoma including typical or atypical carcinoid, large-cell neuroendocrine carcinoma; d. mutant type of driven genes; e. Stage I and IV (AJCC 8th Edition) confirmed by cranial MRI, chest CT, abdominal ultrasonograph, bone scan or cranial MRI and PET-CT; f. surgically resectable; g. no signature of inform consent.
Staging Examination before Radiotherapy: a. ECOG scoring. b. Cranial contrast MRI and PET-CT, or cranial contrast MRI (preferred), chest contrast CT, abdominal ultrasonography and bone scan. c. Bronchoscopy for centrally-located lung cancer. d. Staging examination is mandatory after inductive chemotherapy & chemotherapy with immunotherapy. e. Pulmonary function test.
Inductive therapy before radiotherapy: Chemotherapy or chemotherapy combined with immunotherapy is allowed as inductive therapy. Detailed regimen could refer to NCCN guidelines. Tyrosine kinase inhibitors are not allowed as inductive therapy.
Randomization: Patients would be randomly assigned to high dose group and low dose group using random number table method.
Radiotherapy CT simulation: 4-Dimensional CT (4D-CT) with intravenous contrast is recommended for simulation. Scan thickness should be less than 5 mm. Thermal mask or vacuum bag is recommended.
Target Delineation: Considering hypofraction and involved field irradiation (IFI), only Internal Tumor Volume (ITV) should be delineated without the need to delineate Clinical Tumor Volume (CTV).
Delineation of ITV: ITV should include pulmonary gross tumor and metastatic mediastinal lymph nodes. PET-CT registration with simulation CT is recommended for patients with obstructive atelectasis. For patients with suspected mediastinal lymph nodes, Endobronchial Ultrasound-guided Transbronchial Needle Aspiration (EBUS-TBNA) is recommended.
Production of Planning Tumor Volume (PTV):
Low-dose Arm (48Gy/12f) PTV: PTV is produced by a margin of 5 mm added to ITV. Modification of PTV is suggested to respect anatomic boundary.
High-dose Arm (60Gy/15f) PTV: Planning Tumor Volume (PTV) is produced by a margin of 5 mm added to ITV. Modification of PTV is suggested to respect anatomic boundary.
The protection of OAR was given higher priority than the prescription dose coverage of PTV. The dose to PTV in adjacent to or abutting esophagus and spinal cord could be compromised with the lowest coverage rate of 90%.
Dosimetric Limitation:
Total Lung: V20<23%, Dmean<13Gy, V5<50%. Spinal Cord: Dmax<40Gy. Heart:V42<15cc, Dmax<48.9Gy in high-dose arm, V36.6<15cc, Dmax<42.5Gy in low-dose arm.
Great Vessels: V57<10cc,Dmax<65Gy in high-dose arm, V55.7<10cc,Dmax<62.9Gy in low-dose arm.
Esophagus: V45<2.5cc in high-dose arm, V40<2.5 cc in low-dose arm. Proximal Bronchial Tree: V55.5<5cc, Dmax<65Gy in high-dose arm, V52<5cc, Dmax<59Gy in low-dose arm.
Branchial Plexus: V48<3cc, Dmax<52.5Gy in high-dose arm, V37<3cc, Dmax<43Gy in low-dose arm.
Treatment Implementation: Radiotherapy is implemented every day. Cone-beam CT should utilized every day to minimize set-up error.
Concurrent Chemotherapy:For patients who have received over 4 cycles of inductive chemotherapy with or without immunotherapy, no concurrent chemotherapy is needed. For patients who had not received induction therapy or less than 4 cycles of inductive chemotherapy with or without immunotherapy, concurrent chemotherapy is needed to ensure 4 cycles of chemotherapy. Adenocarcinoma: Pemetrexed combined with platinum is recommended. Squamous-cell lung cancer: Etoposide combined with platinum is recommended. One month after completion of radiotherapy, chest CT and abdominal ultrasonography should be undertaken. After exclusion of disease progression and grade 2 or more radiation-induced pneumonitis, consolidative immunotherapy should be started. Durvalumab maintenance for one year is recommended.
Follow-up: Patients should be follow-up every three months right after the completion of radiotherapy to 3 years after radiotherapy. Then follow-up every half year is allowed to 5 years after radiotherapy. After 5 years, follow-up every year is appropriate. In follow-up, chest CT and abdominal ultrasonography should be implemented. Cranial MRI should be performed every half year for patients with adenocarcinoma. Bone scan should be undertaken every year for all patients.
Primary Endpoint: Rate of radiation-induced pneumonitis, esophagitis, central hilar structure injury rate, hematologic toxicity (CTCAE V4.0).
Secondary Endpoint: Median overall survival, 2-year overall survival rate, Median progression-free survival, 2-year progression-free survival, Objective response rate, Complete response rate, Partial response rate (RECIST v1.1).
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 2
Contacten en locaties
Studie Locaties
-
-
Anhui
-
Hefei, Anhui, China
- Anhui Provicial Hospital
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- 18-70 years old;
- Eastern Cooperative Oncology Group (ECOG) 0-1;
- Non-small cell lung cancer including squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma, large-cell carcinoma;
- Wild-type of driven genes;
- Stage II-III (AJCC 8th Edition) confirmed by cranial MRI, chest CT, abdominal ultrasonograph, bone scan or cranial MRI and d Positron Emission Tomography (PET-CT);
- Surgically unresectable or deny of surgery;
- Signature of inform consent.
Exclusion Criteria:
- Younger than 18 years old or older than 70 years old;
- ECOG>1;
- Small-cell lung cancer and other neuroendocrine carcinoma including typical or atypical carcinoid, large-cell neuroendocrine carcinoma;
- Mutant type of driven genes;
- Stage I and IV (AJCC 8th Edition) confirmed by cranial MRI, chest CT, abdominal ultrasonograph, bone scan or cranial MRI and PET-CT;
- Surgically resectable;
- No signature of inform consent.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: High-dose Arm
Irradiation of 60Gy/15f is administered followed by one-year immunotherapy maintenance. |
Patients in this arm would receive high-dose fractionated radiotherapy with 60Gy/15f with one-year immunotherapy maintenance. |
|
Experimenteel: Low-dose Arm
Irradiation of 48Gy/12f is administered followed by one-year immunotherapy maintenance. |
Patients in this arm would receive high-dose fractionated radiotherapy with 48Gy/12f with one-year immunotherapy maintenance. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Rate of radiation-induced pneumonitis (CTCAE V4.0)
Tijdsspanne: 1 to 2 years
|
Rate of radiation-induced pneumonitis (CTCAE V4.0) |
1 to 2 years
|
|
Rate of radiation-induced esophagitis (CTCAE V4.0)
Tijdsspanne: 1 to 2 years
|
Rate of radiation-induced esophagitis (CTCAE V4.0) |
1 to 2 years
|
|
Rate of central hilar structure injury (CTCAE V4.0)
Tijdsspanne: 1 to 2 years
|
Rate of central hilar structure injury (CTCAE V4.0) |
1 to 2 years
|
|
Rate of hematologic toxicity
Tijdsspanne: 1 to 2 years
|
Rate of hematologic toxicity |
1 to 2 years
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Median overall survival (RECIST 1.1)
Tijdsspanne: 1-2 year
|
Median overall survival (RECIST 1.1) |
1-2 year
|
|
2-year overall survival rate (RECIST 1.1)
Tijdsspanne: 2 year
|
2-year overall survival rate (RECIST 1.1) |
2 year
|
|
Median progression-free survival (RECIST 1.1)
Tijdsspanne: 1-2 year
|
Median progression-free survival (RECIST 1.1) |
1-2 year
|
|
2-year progression-free survival rate (RECIST 1.1)
Tijdsspanne: 2 year
|
2-year progression-free survival rate (RECIST 1.1) |
2 year
|
|
Objective response rate
Tijdsspanne: 3 months after radiotherapy
|
Objective response rate |
3 months after radiotherapy
|
|
Complete response rate
Tijdsspanne: 3 months after radiotherapy
|
Complete response rate |
3 months after radiotherapy
|
|
Partial response rate
Tijdsspanne: 3 months after radiotherapy
|
Partial response rate |
3 months after radiotherapy
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- ky270
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .